These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1983 related items for PubMed ID: 16282508

  • 1. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.
    Pradeep CR, Sunila ES, Kuttan G.
    Integr Cancer Ther; 2005 Dec; 4(4):315-21. PubMed ID: 16282508
    [Abstract] [Full Text] [Related]

  • 2. Angiogenesis--a new target for future therapy.
    Pandya NM, Dhalla NS, Santani DD.
    Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
    [Abstract] [Full Text] [Related]

  • 3. Vascular endothelial growth factor receptors: expression and function in solid tumors.
    Wey JS, Stoeltzing O, Ellis LM.
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):37-45. PubMed ID: 16163158
    [Abstract] [Full Text] [Related]

  • 4. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
    Hicklin DJ, Ellis LM.
    J Clin Oncol; 2005 Feb 10; 23(5):1011-27. PubMed ID: 15585754
    [Abstract] [Full Text] [Related]

  • 5. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
    Shibuya M.
    FEBS J; 2009 Sep 10; 276(17):4636-43. PubMed ID: 19664071
    [Abstract] [Full Text] [Related]

  • 6. VEGF as a key mediator of angiogenesis in cancer.
    Carmeliet P.
    Oncology; 2005 Sep 10; 69 Suppl 3():4-10. PubMed ID: 16301830
    [Abstract] [Full Text] [Related]

  • 7. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
    Guo Y, Wang S, Hoot DR, Clinton SK.
    J Nutr Biochem; 2007 Jun 10; 18(6):408-17. PubMed ID: 17142033
    [Abstract] [Full Text] [Related]

  • 8. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.
    Clin Cancer Res; 2009 Mar 01; 15(5):1612-22. PubMed ID: 19223496
    [Abstract] [Full Text] [Related]

  • 9. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis.
    Jośko J, Gwóźdź B, Jedrzejowska-Szypułka H, Hendryk S.
    Med Sci Monit; 2000 Mar 01; 6(5):1047-52. PubMed ID: 11208453
    [Abstract] [Full Text] [Related]

  • 10. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors.
    Tandle A, Libutti SK.
    Clin Adv Hematol Oncol; 2003 Jan 01; 1(1):41-8. PubMed ID: 16227959
    [Abstract] [Full Text] [Related]

  • 11. Current insights on the biology and clinical aspects of VEGF regulation.
    Birk DM, Barbato J, Mureebe L, Chaer RA.
    Vasc Endovascular Surg; 2003 Jan 01; 42(6):517-30. PubMed ID: 18799497
    [Abstract] [Full Text] [Related]

  • 12. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW, Kim SJ, Choi HJ, Kim KJ, Kim MJ, Kim SH, Lee HJ, Ko JH, Lee YC, Suzuki A, Kim CH.
    Glycobiology; 2009 Mar 01; 19(3):229-39. PubMed ID: 18974200
    [Abstract] [Full Text] [Related]

  • 13. Targeting tumor angiogenesis.
    Gaur P, Bose D, Samuel S, Ellis LM.
    Semin Oncol; 2009 Apr 01; 36(2 Suppl 1):S12-9. PubMed ID: 19393831
    [Abstract] [Full Text] [Related]

  • 14. [Hypoxia and angiogenesis].
    Simon JM.
    Bull Cancer; 2007 Jul 01; 94 Spec No():S160-5. PubMed ID: 17846000
    [Abstract] [Full Text] [Related]

  • 15. VEGF as a therapeutic target in cancer.
    Ferrara N.
    Oncology; 2005 Jul 01; 69 Suppl 3():11-6. PubMed ID: 16301831
    [Abstract] [Full Text] [Related]

  • 16. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.
    Clin Cancer Res; 2008 Apr 01; 14(7):2210-9. PubMed ID: 18381963
    [Abstract] [Full Text] [Related]

  • 17. Vascular endothelial growth factor (VEGF) signaling in tumor progression.
    Roskoski R.
    Crit Rev Oncol Hematol; 2007 Jun 01; 62(3):179-213. PubMed ID: 17324579
    [Abstract] [Full Text] [Related]

  • 18. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
    Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M.
    Cancer Res; 2006 Jun 01; 66(11):5549-54. PubMed ID: 16740688
    [Abstract] [Full Text] [Related]

  • 19. [Neoplasms and angiogenesis].
    Lewy-Trenda I.
    Pol Merkur Lekarski; 2002 Sep 01; 13(75):225-8. PubMed ID: 12474576
    [Abstract] [Full Text] [Related]

  • 20. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis.
    Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, Michel BA, Gay RE, Müller-Ladner U, Matucci-Cerinic M, Plate KH, Gassmann M, Gay S.
    Circ Res; 2004 Jul 09; 95(1):109-16. PubMed ID: 15178641
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 100.